×
About 3,695 results

ALLMedicine™ Peritoneal Cancer Center

Research & Reviews  1,719 results

Validation of 18F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of p...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042953
Cancer Imaging : the Official Publication of the Internat... Jónsdóttir B, Ripoll MA et. al.

Apr 14th, 2021 - The extent of peritoneal carcinomatosis is difficult to estimate preoperatively, but a valid measure would be important in identifying operable patients. The present study set out to validate the usefulness of integrated 18F-FDG PET/MRI, in compar...

Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductiv...
https://doi.org/10.1016/j.ejso.2021.03.239
European Journal of Surgical Oncology : the Journal of Th... Mikkelsen MS, Petersen LK et. al.

Apr 4th, 2021 - Preoperative assessment of peritoneal metastases is an important factor for treatment planning and selection of candidates for cytoreductive surgery (CRS) in primary advanced stage (FIGO stages III-IV) epithelial ovarian cancer (EOC). The primary ...

Early oral feeding is safe and useful after rectosigmoid resection with anastomosis dur...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962404
World Journal of Surgical Oncology; Kato K, Omatsu K et. al.

Mar 16th, 2021 - The aim of this study was to investigate the safety and clinical usefulness of early oral feeding (EOF) after rectosigmoid resection with anastomosis for the treatment of primary ovarian cancer. We performed a retrospective review of all consecuti...

Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, ...
https://doi.org/10.1080/14737140.2021.1880326
Expert Review of Anticancer Therapy; Liu MC, Sutedja J et. al.

Mar 11th, 2021 - Introduction: Approximately 300,000 women worldwide are diagnosed each year with ovarian cancer. Frequently diagnosed in late stages with ambiguous symptomatology, ovarian cancer has a low survival rate.Areas covered: Niraparib, a PARP inhibitor, ...

Exploring the prognostic and therapeutic utility of expanded mutation profiling in appe...
https://doi.org/10.1002/jso.26439
Journal of Surgical Oncology; Zhang C, Plambeck BD et. al.

Mar 5th, 2021 - Interrogation of cancers with next-generation sequencing (NGS) mutation panels has become widely utilized, identifying prognostic and actionable mutations. This study explored the value of expanded mutation analysis in appendix peritoneal metastas...

see more →

Guidelines  21 results

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
https://doi.org/10.1200/JCO.20.01924
Journal of Clinical Oncology : Official Journal of the Am... Tew WP, Lacchetti C et. al.

Aug 13th, 2020 - To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). Randomized, controlled, and open-labeled trials published from 2011 through 2...

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response ...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer...

BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1

Aug 20th, 2019 - The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations...

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer - US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2748515

Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is t...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  1,855 results

Validation of 18F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of p...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042953
Cancer Imaging : the Official Publication of the Internat... Jónsdóttir B, Ripoll MA et. al.

Apr 14th, 2021 - The extent of peritoneal carcinomatosis is difficult to estimate preoperatively, but a valid measure would be important in identifying operable patients. The present study set out to validate the usefulness of integrated 18F-FDG PET/MRI, in compar...

Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductiv...
https://doi.org/10.1016/j.ejso.2021.03.239
European Journal of Surgical Oncology : the Journal of Th... Mikkelsen MS, Petersen LK et. al.

Apr 4th, 2021 - Preoperative assessment of peritoneal metastases is an important factor for treatment planning and selection of candidates for cytoreductive surgery (CRS) in primary advanced stage (FIGO stages III-IV) epithelial ovarian cancer (EOC). The primary ...

NICE Recommends Ovarian Cancer combination Option on Cancer Drugs Fund
https://www.medscape.com/viewarticle/948166

Mar 25th, 2021 - NICE has published draft guidance which recommends olaparib plus bevacizumab for use within the Cancer Drugs Fund (CDF) as an option for maintenance treatment of advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or p...

Early oral feeding is safe and useful after rectosigmoid resection with anastomosis dur...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962404
World Journal of Surgical Oncology; Kato K, Omatsu K et. al.

Mar 16th, 2021 - The aim of this study was to investigate the safety and clinical usefulness of early oral feeding (EOF) after rectosigmoid resection with anastomosis for the treatment of primary ovarian cancer. We performed a retrospective review of all consecuti...

Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, ...
https://doi.org/10.1080/14737140.2021.1880326
Expert Review of Anticancer Therapy; Liu MC, Sutedja J et. al.

Mar 11th, 2021 - Introduction: Approximately 300,000 women worldwide are diagnosed each year with ovarian cancer. Frequently diagnosed in late stages with ambiguous symptomatology, ovarian cancer has a low survival rate.Areas covered: Niraparib, a PARP inhibitor, ...

see more →

News  91 results

NICE Recommends Ovarian Cancer combination Option on Cancer Drugs Fund
https://www.medscape.com/viewarticle/948166

Mar 25th, 2021 - NICE has published draft guidance which recommends olaparib plus bevacizumab for use within the Cancer Drugs Fund (CDF) as an option for maintenance treatment of advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or p...

NICE Approves 'Game-changing' Ovarian Cancer Drug
https://www.medscape.com/viewarticle/944178

Jan 14th, 2021 - Niraparib (Zejula, GlaxoSmithKline) has been approved by the National Institute for Health and Care Excellence (NICE) for England's Cancer Drugs Fund (CDF) for some women with advanced ovarian cancer. The decision means the drug should also be ava...

ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer
https://www.medscape.com/viewarticle/939945

Oct 27th, 2020 - New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC). However, trials investigating retreatment are underway, so this recommend...

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response ...

see more →